Actively Recruiting
Impact of Implementation Strategies on Lp(a) Testing in Secondary Care Settings
Led by Novartis Pharmaceuticals · Updated on 2026-04-02
4500
Participants Needed
1
Research Sites
122 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Lipoprotein(a) \[Lp(a)\] is recognised as an independent, non-modifiable genetic risk factor for cardiovascular (CV) disease. Current guidelines from the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) recommend that Lp(a) be measured at least once in every adult's lifetime, however routine Lp(a) testing rates remains infrequent. The aim of this study is to assess the impact of implementation strategies (IStr) designed to increase the adoption of Lp(a) testing in routine practice, ultimately leading to more individuals being tested in secondary care. This, in turn, is expected to result in the identification and enhanced management of Cardiovascular Disease (CVD) risk patients with elevated Lp(a).
CONDITIONS
Official Title
Impact of Implementation Strategies on Lp(a) Testing in Secondary Care Settings
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Lp(a) testing is available and reimbursed at the healthcare center
- Center can increase Lp(a) testing rates among eligible patients
- Current Lp(a) testing rate at center is less than 15% for eligible patients
- Willingness to fulfill research requirements such as repurposing clinic data
- Center sees a defined number of eligible patients per year for study sample size
- Local infrastructure and data interoperability are available
- Healthcare professionals are cardiovascular specialists or manage cardiovascular risk at their centers
- Patients are over 18 years old and qualify for Lp(a) testing according to local practice
- Patients attend at least one secondary care visit during specified study periods
- Informed consent or waiver obtained before using electronic patient records
You will not qualify if you...
- Centers without access to Lp(a) testing
- Centers where Lp(a) testing is not reimbursed
- Patients who have undergone Lp(a) testing before the study start for post-implementation assessments
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Novartis Investigative Site
Nuremberg, Germany, 90443
Actively Recruiting
Research Team
N
Novartis Pharmaceuticals
CONTACT
N
Novartis Pharmaceuticals
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here